Odonate Therapeutics, Inc. (ODT)
(Delayed Data from NSDQ)
$19.48 USD
+1.36 (7.51%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.48 USD
+1.36 (7.51%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Odonate Therapeutics (ODT) Enters Oversold Territory
by Zacks Equity Research
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Odonate Therapeutics (ODT) is Oversold: Can It Recover?
by Zacks Equity Research
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.
New Strong Sell Stocks for October 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for October 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Are Options Traders Betting on a Big Move in Odonate Therapeutics (ODT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.
Why Odonate Therapeutics (ODT) Stock Might be a Great Pick
by Zacks Equity Research
Odonate Therapeutics (ODT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Odonate Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Odonate Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer Homes USA and NVIDIA
by Zacks Equity Research
Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer Homes USA and NVIDIA
Odonate Therapeutics Enters Oversold Territory
by Zacks Equity Research
Odonate Therapeutics, Inc. (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
4 of the Best Stocks With Solid Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.
Small Drug Stocks Outlook: Near-Term Prospects Encouraging
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.
Can The Uptrend Continue for Odonate Therapeutics (ODT)?
by Zacks Equity Research
Investors certainly have to be happy with Odonate Therapeutics, Inc. (ODT) and its short term performance